Table 3.

Effect of sacubitril/valsartan on serum potassium in patients with HF.

Study	Comparator	Patient population, ARNI/comparator ( n )	Median duration of follow-up	Incidence of moderate to severe hyperkalemia		p value
				ARNI	Comparator
PARAMOUNT, Solomon et al. [57]	Valsartan	Patients with HFpEF, 149/152	36 weeks	24 (16%)	16 (11%)	0.21
PARADIGM-HF, McMurray et al. [49]	Enalapril	Patients with HFrEF, 4187/4212	27 months	674 (16.1)	727 (17.3)	0.15
PARAGON-HF, Solomon et al. [53]	Valsartan	Patients with HFpEF, 2407/2389	35 months	316 (13.1)	361/2367 (15.1)	0.048
PIONEER-HF, Velazquez et al. [54]	Enalapril	HFrEF patients hospitalized for ADHF, 440/441	8 weeks	51 (11.6)	41 (9.3)	> 0.05

Note: Moderate to severe hyperkalemia was defined as serum potassium > 5.5 mmol/L.